Nakamura Choukou (6166) · InitiativeAdvanced
Considering an Investment in the Specialty Peptide API Business
First written in FY2018-Q2. 1 of 2 entries say "Advanced", first in FY2019. Latest entry: FY2019.
2entries
3years
0from disclosures
How it moved
Same theme, other companies
Establishing a CMO platform for specialized peptide pharmaceuticals through PeptiStarA theme 2 companies write about · 0 as a headwind · 2 as a tailwind
1 other company's latest entry also says "Advanced".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
- FY2019AdvancedAnnual report
「Unlisted shares 1 200,000 To launch a new business by subscribing for part of the shares」
The company acquired ¥200 million of unlisted shares to launch a new business. - FY2018-Q2First statedAnnual report
「The funds are intended to finance capital expenditures to increase diamond wire production and an investment currently under consideration in Pepster Corporation (*2). Pepster Corporation is a new company established in September 2017 through a joint venture among Peptide Dream Inc., Shionogi & Co.,Ltd., and Sekisui Chemical Co.,Ltd. (collectively, the “three companies”) to conduct research and development, manufacture, and sales of specialty-peptide active pharmaceutical ingredients (*3).」
The intended use of proceeds for the first time included the investment currently under consideration in Pepster Corporation, which was established in September 2017 to conduct research and development, manufacture, and sales of specialty-peptide active pharmaceutical ingredients.